Assertio Shareholders to Benefit from 75.8% Premium in Zydus All-Cash Acquisition

Board Approves Superior $23.50 Per Share Cash Offer from Zydus

Assertio Holdings (NASDAQ: ASRT) is set to be acquired by Zydus Worldwide DMCC for $23.50 per share in cash, according to the company’s latest announcement. The all-cash offer amounts to a total valuation of approximately $166.4 million—capping off a strategic review that saw Assertio’s board unanimously endorse the Zydus proposal as the best path forward for shareholders.

Zydus Offer Outpaces Previous Bids with a Strong Premium

The Zydus deal stood out for several reasons. Most notably, the offer represents a substantial 75.8% premium to Assertio’s unaffected closing stock price as of March 20, 2026. This surpasses offers made earlier by Garda Therapeutics, which included an $18.00 per share bid (April 8, 2026) and a revised $21.80 per share bid (May 4, 2026). The Zydus bid is not just higher in price but also superior in deal certainty—backed with no financing contingencies and guarantees from a creditworthy Zydus entity.

Transaction Certainty: No Financing Hurdles, Swift Timeline Expected

The board’s decision factored in not just pricing, but execution certainty and risk mitigation. Unlike many acquisition proposals, Zydus’ offer carries no financing contingencies, is fully backed, and requires no third-party financing. The process will begin with a tender offer for all outstanding shares and is anticipated to close in the second quarter of 2026, provided that a majority of shares are tendered. Notably, the board’s recommendation is unanimous, giving added confidence to shareholders.

Shareholders Face Key Dates as Listing Nears End

Upon closure, Assertio common stock will be delisted from Nasdaq. The company will also file required updates with the SEC so investors can track progress and review transaction terms in detail. The absence of regulatory hurdles further streamlines the timeline for closing, reducing uncertainty for investors.

Premium Buyout Provides Clear Path for Assertio Investors

For current Assertio shareholders, this acquisition represents a notable opportunity to realize significant value—well above previous buyout offers and unaffected price levels. With deal certainty bolstered by Zydus’ financial strength and a swift, expected closure, investors face a straightforward decision as the tender offer commences. Those wanting the full details should watch for the forthcoming SEC filings, including Schedule 14D-9 and related disclosures.

Key Takeaway: The Superior Bid Locks in Value

In a competitive acquisition landscape, Assertio’s board chose a route that maximizes both price and certainty. The Zydus transaction isn’t just a higher price—it’s a package with minimized execution risk and a premium that stands out among pharmaceutical sector buyouts. Shareholders should monitor the required filings as the process unfolds for final closure steps and any potential competing bids.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI